Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue…
Companies, HIV-1 background & Clinical trials
Explore the main themes, entities and connections around Vicriviroc. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
ccr5 hiv-1 gp120 coreceptor virus patients hiv trials viral cell two may however antagonists gp41 cxcr4 target one entry clinical
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| vicriviroc | instance of | CCR5 inhibitors | 0.80 | text |
| as well as other entry inhibitors of HIV-1 | instance of | CCR5 inhibitors | 0.80 | text |
| inhibit the initial stages of the virus life cycle.HIV-1 entryHIV binds to | instance of | CCR5 inhibitors | 0.80 | text |
| fuses with the target T-cells or macrophages with the help of gp120 | instance of | CCR5 inhibitors | 0.80 | text |
| gp41 | instance of | CCR5 inhibitors | 0.80 | text |
| the only two proteins that are currently known to be exhibited on the surface of the viral envelope | instance of | CCR5 inhibitors | 0.80 | text |
| Vicriviroc | related to background | The | 0.60 | section |
| Vicriviroc | related to background | HIV | 0.60 | section |
| Vicriviroc | related to background | However | 0.60 | section |
| Vicriviroc | related to background | CCR5 | 0.60 | section |
| Vicriviroc | related to background | HIV-1 | 0.60 | section |
| Vicriviroc | related to Clinical trials | Currently | 0.60 | section |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.